Technical Analysis for ATNM - Actinium Pharmaceuticals, Inc. (Delaware)

Grade Last Price % Change Price Change
grade D 0.2453 -1.88% 0.00
ATNM closed up 0.68 percent on Thursday, November 14, 2019, on 18 percent of normal volume.
5 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Down
See historical ATNM trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish -1.88%
1,2,3 Pullback Bullish Bullish Swing Setup -1.88%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.88%
Wide Bands Range Expansion -1.88%
Fell Below 20 DMA Bearish -1.21%
1,2,3 Pullback Bullish Bullish Swing Setup -1.21%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.21%
Stochastic Reached Oversold Weakness -1.21%
Outside Day Range Expansion -1.21%
Wide Bands Range Expansion -1.21%

Older signals for ATNM ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators
ATNM Chart by TradingView
Basic chart:
Profile
Actinium Pharmaceuticals, Inc., formerly Cactus Ventures, Inc. is a biopharmaceutical company developing cancer drugs. The Company's advanced products are Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), in human clinical trials for acute myeloid leukemia (AML) and Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. In addition, the Ac-225 based drugs development relies on the patented Alpha Particle Immunotherapy Technology (APIT) platform technology co-developed with Memorial Sloan- Kettering Cancer Center (MSKCC), a related institution. The APIT technology couples monoclonal antibodies (mAb) with extremely potent but comparatively safe alpha particle emitting radioactive isotopes, in particular actinium 225 and bismuth 213.
Chemistry Biopharmaceutical Cancer Physical Sciences Natural Sciences Immunology Antibodies Chemical Elements Stem Cells Acute Myeloid Leukemia Monoclonal Antibody Platform Technology Transplantation Actinides
Is ATNM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Nov 7 Actinium Pharmaceuticals to Present at the 25th Annual BIO-Europe® 2019 International Partnering Conference
Nov 6 Actinium Announces Interim Results from Phase 1 Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML Accepted for Presentation at ASH 2019
Nov 6 Actinium Pharmaceuticals to Present New Clinical Findings from SIERRA Trial Supporting the Iomab-ACT Program for Targeted Lymphodepletion for CAR-T and Adoptive Cell Therapies at ASH 2019
Oct 28 Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment
Oct 15 What Kind Of Investor Owns Most Of Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM)?
Sep 30 Actinium Announces Participation at the 2019 Cell & Gene Meeting on the Mesa
Sep 23 Actinium Announces Iomab-B Poster Selected for Honorable Distinction Award at the 2019 Society of Hematologic Oncology Annual Meeting from Nearly Four Hundred Abstracts
Sep 16 Actinium Pharmaceuticals to Present at the Sachs 19th Annual Biotech in Europe Forum for Global Partnering & Investment
Aug 8 Sell-siders trim views on Inogen after Q2 miss and guidance cut
Aug 6 The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering
See more ATNM news...
Indicators
Indicator Value
52 Week High 0.71
52 Week Low 0.19
Average Volume 1,639,589
200-Day Moving Average 0.3306
50-Day Moving Average 0.2332
20-Day Moving Average 0.255
10-Day Moving Average 0.2615
Average True Range 0.0272
ADX 30.35
+DI 28.0231
-DI 16.6667
Chandelier Exit (Long, 3 ATRs ) 0.3284
Chandelier Exit (Short, 3 ATRs ) 0.2787
Upper Bollinger Band 0.3203
Lower Bollinger Band 0.1897
Percent B (%b) 0.46
BandWidth 51.215686
MACD Line 0.0076
MACD Signal Line 0.0099
MACD Histogram -0.0023
Fundamentals Value
Market Cap 20 Million
Num Shares 80 Million
EPS -0.52
Price-to-Earnings (P/E) Ratio -0.48
Price-to-Sales 0.00
Price-to-Book 4.30
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.27
Resistance 3 (R3) 0.27 0.27 0.27
Resistance 2 (R2) 0.27 0.26 0.27 0.27
Resistance 1 (R1) 0.26 0.26 0.26 0.26 0.27
Pivot Point 0.25 0.25 0.25 0.25 0.25
Support 1 (S1) 0.24 0.24 0.25 0.24 0.23
Support 2 (S2) 0.23 0.24 0.23 0.23
Support 3 (S3) 0.23 0.23 0.23
Support 4 (S4) 0.23